Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

To join this study, you must be an adult aged 18 or over. For those with Diffuse Large B-Cell Lymphoma (DLBCL), your cancer must have come back or not responded after at least two other treatments. If you can't have a stem cell transplant, you might be able to join after just one previous treatment. For those with Chronic Lymphocytic Leukaemia (CLL), your cancer must have come back or not responded after at least one previous treatment.

Crucially, your specific type of cancer cells must have a normal 'TP53' gene. This is something your doctor can check. You also need to be generally well enough to take part, as measured by a health score called ECOG (this usually means you can carry out most daily activities). Your liver, kidney, and blood functions must also be healthy enough.

However, you cannot take part if you have previously been treated with certain types of cancer medicines. This includes any medicine that works like KRT-232 (an MDM2 inhibitor) or any medicine like acalabrutinib (a BTK inhibitor).

If you decide to take part in this study, you will receive two study medications, KRT-232 and acalabrutinib. Both of these are taken by mouth. You will have regular appointments at the hospital or clinic, where the study team will monitor your health closely. This will involve physical examinations, blood tests, and scans to see how your body is reacting to the treatment and if your cancer is responding.

The number of visits and tests might be more frequent at the beginning of the study. You will continue to take the medication and have regular check-ups as long as the treatment is helping you and you are not experiencing significant side effects. After you stop taking the study medication, there will be follow-up appointments to monitor your long-term health. The total duration of your participation, including follow-up, will depend on your individual response and how long you remain on treatment.